Tracking the Battle Against Breast Cancer With New Market Research
FARMINGTON, Conn., Jan. 29, 2013 /PRNewswire-iReach/ -- Breast cancer is the most diagnosed cancer in women and is the leading cause of death among women globally. Increased public awareness and improved screening have led to earlier diagnosis, significantly improving survival rates, particularly in younger women. Unfortunately, many early breast cancer growths are not associated with pain or discomfort, and therefore are first detected as abnormalities on mammograms before patients or healthcare providers notice them.
Global Information (GII) highlights three market research reports covering the breast cancer market, drug pipeline and partnering deal activities. The reports will help participating organizations benchmark their own developments against worldwide data, compare portfolio and therapy focus with peers, jumpstart competitive drug intelligence operations, and more.
Time is running out to register for the Molecular Med Tri-Con 2013, which will feature conference programs in the following channels: diagnostics, therapeutics, clinical, informatics, and cancer.
Molecular Med Tri-Con 2013| February 11 – 15, 2013 | San Francisco, CA
Visit https://www.giiresearch.com/conference/en/order/246560 to register today
Breast Cancer Drug Pipeline Update 2013
There are currently 351 companies plus partners who are developing 479 drugs targeting breast cancer across 247 different targets. In addition, there are 7 suspended drugs and another 185 drugs where development has been ceased.
This report provides world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 247 different targets. These targets are further categorized on in the software application by 61 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bg171732-breast-cancer.html
Breast Cancer Diagnostic and Drug Technologies: Global Markets
The market for predictive diagnostic and drug technologies for breast cancer was valued at $21.2 billion in 2011. This figure is projected to reach nearly $24.1 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.5%.
Breast cancer drugs accounted for $10.2 billion in 2011 and should total $11.2 billion in 2016, a CAGR of 1.9%. Quantitative immunofluorescence totaled $5.9 billion in 2011 and should reach $6.9 billion in 2016, a CAGR of 3.1%. Genomic analysis was worth $4.4 billion in 2011 and in 2016 should be worth nearly $5.2 billion, a CAGR of 3.1%. IHC and FISH accounted for nearly $678 million in 2011 and are expected to be worth nearly $788 million in 2016, a CAGR of 3.1%.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc245536-breast-cancer-diagnostic-drug-technologies-global.html
Breast Cancer Partnering 2007-2012
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report provides an analysis of breast cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors breast cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/wild233895-breast-cancer-partnering-2007-2012.html
For more market research highlights, technical research news and industry updates, please visit http://www.giiresearch.com/press/
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.